Adoptive T-Cell Therapy for Solid Malignancies.


Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, CRC Building 10, Room: 3-3832, Bethesda, MD 20892, USA. Electronic address: [Email]


The use of immunotherapies for solid and hematologic malignancies has demonstrated durable antitumor effects. Use of checkpoint inhibitors allows for immunologic reactivation of the adaptive immune system against tumor-specific neoantigens and effective rejection. Recent developments in adoptive transfer of T cells has shown effective immune rejection of solid malignancies and durable regression. Adoptive cell transfer involves extraction of in vivo T lymphocytes, selection for or introduction of tumor reactive cells, in vitro expansion, and delivery of the T-cell product back to the patient. This article discusses the different approaches, challenges, and further directions of adoptive T-cell transfer in solid malignancies.


Adoptive T-cell transfer,Chimeric antigen receptor T cell,Gene engineered T-cell receptor,Neoantigens,Tumor-infiltrating lymphocytes,